IPO registrations (S-1, F-1) · Registrants
Sucampo Pharmaceuticals, Inc.
- SEC CIK
- 1365216 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2006-06-19, last 2007-07-30; 1 initial registration, 9 amendments
- Outcome
- Final prospectus filed 2007-08-03; declared effective 2007-08-02
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Business address
- 805 KING FARM BOULEVARD, SUITE 550, Rockville, MD 20850
- EIN
- 13-3929237
- EDGAR entity type
- operating
- Insiders and CEO pay
- Sucampo Pharmaceuticals, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2007-07-30)
- Final price
- $8.29 per share, below the range (424B4 filed 2007-08-03, an initial public offering)
- Shares sold
- 3,750,000 (3,125,000 by the company, 625,000 by selling holders)
- Gross proceeds
- $31,087,500 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol SCMP
- Lead underwriters
- Cowen (1,875,000 shares)
- Syndicate
- CIBC World Markets (1,050,000); Leerink Partners (825,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: SUCAMPO PHARMA AMERICAS, LLC EXACT (EIN (EXACT))
- Federal award recipient: SUCAMPO PHARMACEUTICALS, INC. Fuzzy (name and state)
- Lobbying client: SUCAMPO PHARMACEUTICALS Fuzzy (name and state)
- Lobbying client: SUCAMPO PHARMACEUTICALS INC. Fuzzy (name and state)
- Lobbying client: SUCAMPO PHARMACEUTICALS, INC. Fuzzy (name and state)
- Lobbying client: SUCAMPO PHARMACEUTICALS, INC. Fuzzy (name and state)
- SEC filer: Sucampo Pharmaceuticals, Inc. EXACT (CIK (EXACT))
- Person page: Timothy P Walbert Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 12
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2006-06-19 | S-1 | S-1 (registration) | Sucampo Pharmaceuticals, Inc. | 0000950133-06-003016 ↗ |
| 2006-08-11 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-06-003747 ↗ |
| 2006-10-20 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-06-004511 ↗ |
| 2006-10-25 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-06-004562 ↗ |
| 2006-11-14 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-06-004996 ↗ |
| 2007-02-01 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-07-000302 ↗ |
| 2007-05-14 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-07-002342 ↗ |
| 2007-06-25 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-07-002785 ↗ |
| 2007-07-17 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-07-002945 ↗ |
| 2007-07-30 | S-1/A | S-1/A (amendment) | Sucampo Pharmaceuticals, Inc. | 0000950133-07-003113 ↗ |
| 2007-08-02 | EFFECT | EFFECT (declared effective) | Sucampo Pharmaceuticals, Inc. | 9999999995-07-003090 ↗ |
| 2007-08-03 | 424B4 | 424B4 (final prospectus) | Sucampo Pharmaceuticals, Inc. | 0000950133-07-003192 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2007-07-30 | S-1/A | registration statement | $14.00–$16.00 | 3,750,000 | - | Nasdaq SCMP | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2007-08-03 | 424B4 | final prospectus | $8.29 | 3,750,000 | $31,087,500 | Nasdaq SCMP | 3 | primary document; price line, shares headline, proceeds computed, underwriting table 3, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Astellas Pharma Inc. | Other; TenPercentOwner | 2 | 2007 | ||
| Dolecek Gayle R | Director; Director,Officer; Officer | SVP Research & Development; VP of Research and Development; VP of Research & Development | 8 | 2007–2014 | |
| Fackler Brad E | Officer | EVP Commercial Operations | 2 | 2007 | |
| Hrushka Charles S | Officer | VP Marketing | 1 | 2007 | |
| JEFFRIES MICHAEL J | Director | 1 | 2007 | ||
| KAISER RONALD W | Officer | CFO | 2 | 2007 | |
| Kuno Sachiko | Director,TenPercentOwner; TenPercentOwner | 56 | 2007–2018 | ||
| MAUDLIN TIMOTHY I | Director | 6 | 2007–2013 | ||
| Mine Hidetoshi | Director,TenPercentOwner | 3 | 2007–2008 | ||
| Molina V Sue | Director | 1 | 2007 | ||
| Morris Mariam E | Officer | Chief Acctg. Officer, Treas. | 2 | 2007 | |
| OPE Limited Partnership 2 | TenPercentOwner | 1 | 2007 | ||
| Ridgeway Capital Partners LTD | TenPercentOwner | 2 | 2007 | ||
| R-Tech Ueno, Ltd. | TenPercentOwner | 2 | 2007 | ||
| S&R Technology Holdings, LLC | Other; TenPercentOwner | 50 | 2007–2016 | ||
| Tolliver Kei S | Director; Officer | VP Bus. Dev. & Co. Ops., Sec. | 7 | 2007–2015 | |
| Ueno Ryuji | Director,Officer,TenPercentOwner; TenPercentOwner | CEO & Chief Scientific Officer; CEO, Chief Scientific Officer | 57 | 2007–2018 | |
| Celeste Anthony C. | Director | 10 | 2007–2015 | ||
| WRIGHT JOHN C | Director | 2 | 2008 | ||
| Smilek Jan | Officer | Chief Accounting Officer | 3 | 2008–2010 | |
| FERRARA ANDREW J | Director | 4 | 2008–2011 | ||
| Miele Stanley G | Director; Officer | Chief Commercial Officer; President; President, SPA, Inc.; SVP, Sales and Marketing; SVP Sales & Marketing; SVP, Sales & Marketing | 12 | 2008–2015 | |
| Egan James | Director; Officer | Chief Operating Officer | 5 | 2009–2011 | |
| Ashton William | Director | 8 | 2009–2015 | ||
| Knapp Thomas J | Director; Officer; Other | EVP, Chief Legal Ofc, Corp Sec; SVP; SVP, Gen Counsel & Corp. Secy | 6 | 2010–2015 | |
| Nantahala Capital Management, LLC | TenPercentOwner | 2 | 2011–2012 | ||
| Getman Daniel P | Director | 9 | 2011–2016 | ||
| Claiborne Cary J | Officer; Other | Chief financial officer; Chief Financial Officer | 19 | 2011–2014 | |
| ORIX CORP | TenPercentOwner | 1 | 2012 | ||
| MUNDER BARBARA A | Director | 5 | 2013–2015 | ||
| OCONNELL MAUREEN | Director | 8 | 2013–2018 | ||
| Greenleaf Peter | Director,Officer; Officer | CEO; Chief Executive Officer | 17 | 2014–2018 | |
| JOHNSON JOHN | Director | 6 | 2014–2018 | ||
| Spiegel Robert J. | Director | 6 | 2015–2018 | ||
| Smith Andrew P | Officer | Chief Financial Officer | 10 | 2015–2017 | |
| Kiener Peter A | Officer | Chief Science Officer; Chief Scientific Officer | 15 | 2015–2018 | |
| Donley Matthew Maxwell | Officer | EVP, Global HR, IT & Strategy; EVP, Human Resources; Exec.VicePres,HumanResources; Exec. V.P., Human Resources | 15 | 2015–2018 | |
| Lichtlen Peter | Officer | Chief Medical Officer | 5 | 2015–2018 | |
| Walbert Timothy P | Director | 5 | 2015–2018 | person page Fuzzy | |
| Alder Matthias | Officer | EVP, Bus. Dev.&Lic, G.C. &Sec.; EVP, Bus.Dev.&Lic, G.C. &Sec.; EVP, Bus.Dev.&Lic., GC & Sec; EVP, Business Dev. & Licensing; EVP, Gen. Council & Sec. | 12 | 2015–2017 | |
| Edick Paul R | Director | 5 | 2016–2018 | ||
| PFREUNDSCHUH PETER P. | Officer | CFO | 4 | 2017–2018 | |
| Driggs Alex | Officer | Acting General Counsel; General Counsel & Corp. Sec. | 6 | 2017–2018 | |
| Meyenburg Jason Patrick | Officer | Chief Commercial Officer | 3 | 2017–2018 | |
| Bryan Jones W. | Officer | Sr. Vice Pres., BD & Licensing | 4 | 2017–2018 | |
| Smith Karen L. | Director | 2 | 2017–2018 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Federal award recipient | SUCAMPO PHARMACEUTICALS, INC. | MD | Federal spending (USAspending) | name and state |
| Lobbying client | SUCAMPO PHARMACEUTICALS | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | SUCAMPO PHARMACEUTICALS INC. | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | SUCAMPO PHARMACEUTICALS, INC. | MD | Federal lobbying (LDA) | name and state |
| Lobbying client | SUCAMPO PHARMACEUTICALS, INC. | MD | Federal lobbying (LDA) | name and state |
| SEC filer | Sucampo Pharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Sucampo Pharmaceuticals, Inc. | MD | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | SUCAMPO PHARMA AMERICAS, LLC | EIN (EXACT) | ||
| Person page | Timothy P Walbert | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, MD first:
- NORTHWEST BIOTHERAPEUTICS INC MD
- UNITED THERAPEUTICS Corp MD
- INTERCELL USA, INC. MD
- MACROGENICS INC MD
- MiddleBrook Pharmaceuticals, Inc. MD
- AVALON PHARMACEUTICALS INC MD
- IGC Pharma, Inc. MD
- CNBX Pharmaceuticals Inc. MD
- PRECIGEN, INC. MD
- SUPERNUS PHARMACEUTICALS, INC. MD
In other datasets, the same topic (Health) in MD:
- Nonprofit: 4K FOR CANCER INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health